In an effort to identify therapeutic options for AML patients who progress on BCL2 directed therapy, we evaluated a clinical-stage CDK7 inhibitor XL102, which is being evaluated in solid tumors (NCT04726332). Here, CDK7 is linked to acute myeloid leukemia.